David Huang
Senior Director OBI Pharma, Inc.
Dr. David Teng-Yi Huang leads the development of OBI Pharma’s next-generation ADC technologies, including GlycOBI®, ThiOBI®, EndoSymeOBI®, HYPrOBI® and GlycOBI DUO®. With deep expertise in carbohydrate chemistry and glycoengineering, he focuses on designing site-specific, homogeneous ADCs to improve stability, manufacturability, and applicability.
Under his leadership, OBI has advanced multiple clinical and preclinical ADC candidates. Dr. Huang is also a key contributor to OBI’s intellectual property portfolio and plays an active role in global business development.
He received his Ph.D. in Chemistry from National Tsing Hua University and completed postdoctoral training at Academia Sinica, where he specialized in glycoscience for biomedical applications.
Seminars
- Employing innovative conjugation chemistry to deliver two distinct payloads to the antibody Fc region
- Optimizing conjugation process across DAR fine tuning and payload selection to reduce dual payload ADC aggregation and enhance developability while accelerating optimal drug candidate selection
- Showcasing impact of discovery-stage innovation to deliver ADC properties and differentiation potential to patients
